FDA approves Eylea for treatment of diabetic macular edema

The U.S. Food and Drug administration has approved Eylea for treatment of diabetic macular edema, according to a Regeneron Pharmaceuticals press release.This is the third FDA-approved indication for the aflibercept injection, which was approved for treatment of neovascular age-related macular degeneration in 2011 and for treatment of macular edema following central retinal vein occlusion in 2012.

Full Story →